Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Ipsen is acquiring Epizyme for about $247 million upfront plus a CVR that could add up to $4 per share in deferred milestones, handing the French pharma an…
French drugmaker Ipsen agreed to buy U.S. biotech Epizyme for about $247 million in cash, it said on Monday, adding a rare cancer drug to its portfolio. Under…
Ipsen voluntarily withdrew tazemetostat from all markets following a safety signal in the confirmatory SYMPHONY-1 trial, where the IDMC flagged adverse events…
Source summaries from our enrichment pipeline; follow links for originals.
All 12 sources with sentiment breakdown →
Ipsen acquired Epizyme for $1.45/share cash (~$247M upfront) plus a non-tradable CVR of up to $4/share, announced June 27, 2022 and closed August 8, 2022. The deal added Tazverik (tazemetostat), a first-in-class FDA-approved EZH2 inhibitor for relapsed/refractory follicular lymphoma and epithelioid sarcoma, plus EZM0414, a Phase 1 SETD2 inhibitor (Fast Track in MM/DLBCL). POST-CLOSE OUTCOME: the thesis did not hold. EZM0414's SET-101 study (NCT05121103) was terminated in 2025 for a 'strategic business decision,' ending the pipeline arm. On March 9, 2026 Ipsen voluntarily withdrew Tazverik in all indications from all markets and discontinued all tazemetostat trials and expanded-access programs, after the confirmatory Phase Ib/III SYMPHONY-1 trial surfaced a safety signal of secondary hematologic malignancies (IDMC: risks may outweigh benefits). With 2025 Tazverik sales of only ~EUR 40.6M (~$47M, -13% YoY), the CVR's $250M sales milestone is effectively unreachable. The acquisition closed as an M&A transaction, but both acquired assets are now off the market or terminated.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Ipsen S.A. / Epizyme Inc. (this deal) | 2022 | $247M | — |
| Ipsen S.A. / Exelixis Inc. | 2016 | $855M | 80 |
| Ipsen S.A. / Kartos Therapeutics, Inc. | 2026 | $1.8B | 68 |
| Ipsen S.A. / Memo Therapeutics AG | 2026 | $797M | 66 |
| Ipsen S.A. / Clementia Pharmaceuticals Inc. | 2019 | $1.3B | — |
| Ipsen S.A. / Marengo Therapeutics, Inc. | 2024 | $1.2B | — |
| Ipsen S.A. / GENFIT | 2021 | $543M | — |
← Browse all deals · How we score deals
More: 2022 deals · Ipsen S.A. deals · Hematology deals